Avelumab

Phase 1Active

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Lymphomas Non-Hodgkin's B-Cell

Conditions

Lymphomas Non-Hodgkin's B-Cell

Trial Timeline

Jul 21, 2017 → Jul 1, 2025

NCT ID

NCT03244176

About Avelumab

Avelumab is a phase 1 stage product being developed by Merck for Lymphomas Non-Hodgkin's B-Cell. The current trial status is active. This product is registered under clinical trial identifier NCT03244176. Target conditions include Lymphomas Non-Hodgkin's B-Cell.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03089658	Pre-clinical	Completed	—	—	Metastatic Merkel Cell Carcinoma
NCT06412848	Pre-clinical	Active	May 9, 2024	Jun 30, 2026	Urothelial Carcinoma
NCT05600127	Phase 2	Recruiting	Dec 1, 2022	Dec 1, 2026	Urothelial Carcinoma
NCT05431777	Pre-clinical	Completed	Jul 19, 2022	Jan 16, 2023	Urothelial Carcinoma
NCT05366725	Pre-clinical	Completed	Jun 29, 2022	Jun 27, 2024	Urothelial Cancer
NCT04822350	Pre-clinical	Completed	Jul 13, 2021	Apr 25, 2024	Urothelial Carcinoma
NCT03815643	Phase 3	Active	Mar 22, 2019	Feb 19, 2027	Solid Tumors
NCT03514719	Phase 1	Completed	Oct 1, 2018	Dec 2, 2021	Non Small Cell Lung Cancer
NCT03568097	Phase 2	UNKNOWN	Sep 16, 2018	Apr 1, 2024	Small Cell Lung Carcinoma
NCT03827044	Phase 3	Terminated	Aug 31, 2018	Jan 5, 2022	POLE Exonuclease Mutant Colon Cancer
NCT03674424	Phase 2	Completed	Jun 1, 2018	Jan 30, 2025	Non-metastatic Muscle Invasive Bladder Cancer
NCT03439501	Phase 2	UNKNOWN	Jan 16, 2018	Mar 30, 2022	Lymphoma, Extranodal NK-T-Cell
NCT03147404	Phase 2	Completed	Dec 28, 2017	Jul 22, 2019	Neuroendocrine Carcinoma, Grade 3
NCT03352934	Phase 2	Completed	Dec 7, 2017	Feb 18, 2022	Cancer
NCT03389126	Phase 2	Completed	Dec 1, 2017	Jan 31, 2020	Carcinoma, Hepatocellular
NCT03278379	Phase 2	Completed	Nov 15, 2017	Jul 6, 2023	Neuroendocrine Tumors
NCT03278405	Phase 1/2	Completed	Nov 15, 2017	Mar 12, 2020	Neuroendocrine Carcinoma
NCT03403777	Phase 2	Completed	Nov 15, 2017	Feb 28, 2019	Testicular Neoplasms
NCT03491345	Phase 2	UNKNOWN	Aug 1, 2017	Dec 1, 2022	PD-L1 Positive Mutation Tumor
NCT03244176	Phase 1	Active	Jul 21, 2017	Jul 1, 2025	Lymphomas Non-Hodgkin's B-Cell

Competing Products

20 competing products in Lymphomas Non-Hodgkin's B-Cell

See all competitors

Product	Company	Stage	Hype Score
ACALABRUTINIB + LISOCABTAGENE MARALEUCEL + Lymphodepleting chemotherapy	Johnson & Johnson	Phase 2	52
Vorinostat + Pegylated Liposomal Doxorubicin (PLD), Doxil	Merck	Phase 1/2	41
MIW815 + PDR001	Novartis	Phase 1	33
ADU-S100 + ipilimumab	Novartis	Phase 1	33
LBH589 and RAD001	Novartis	Phase 1	33
Everolimus + Rituximab	Novartis	Phase 2	52
Placebo + Rituximab + Idelalisib	Gilead Sciences	Phase 3	76
Alobresib + Exemestane + Fulvestrant	Gilead Sciences	Phase 1	32
Idelalisib + Rituximab + Bendamustine + Placebo	Gilead Sciences	Phase 3	76
IBI363	Innovent Biologics	Phase 1	32
IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection	Innovent Biologics	Phase 1	32
MDX-1401	Bristol Myers Squibb	Phase 1	32
BMS-986369	Bristol Myers Squibb	Phase 1/2	40
Alemtuzumab (Campath-1H)	Sanofi	Phase 1/2	40
Tazemetostat + Prednisolone + Tazemetostat	Ipsen	Phase 1/2	38
HMPL-689	HUTCHMED	Phase 1	28
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)	Atara Biotherapeutics	Phase 1/2	33
EBV-specific T cells (EBV-CTLs)	Atara Biotherapeutics	Phase 2	44
LP-284	Lantern Pharma	Phase 1	25
CA-170	Curis	Phase 1	25

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved